Avalon GloboCare Corp.
David Jin, M.D., Ph.D. is currently the Chief Executive Officer and President of Avalon GloboCare Corp. as well as its subsidiary GenExosome Technologies Inc. His passion has been to develop novel products for the treatment and diagnosis based on stem cell-derived technology in order to improve both the quality and length of life of patients. Dr. Jin is a clinician-scientist dedicated to the fields of oncology, hematology, regenerative medicine, and cancer immunotherapy. His work includes his role in biomedical companies and various regulatory agencies internationally as medical reviewers and consultants. Dr. Jin is also a published author and co-author with more than 80 peer reviewed articles, scientific abstracts, reviews, and book chapters featured in publications such as Nature, Nature Medicine, Cell, PNAS and JCI. After he graduated from the combined M.D.-Ph.D. clinician-scientist training program at SUNY Downstate Medical Center’s College of Medicine, Dr. Jin pursued further clinical training, including his fellowship in hematology and medical oncology at NewYork-Presbyterian Hospital. Moreover, Dr. Jin has been senior translational scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Institute at Weil Cornell. His discovery of the chemokine-driven hemangiocytes (bone marrow-derived CXCR4- and VEGFR1-expressing hematopoietic stem cells) in 2006 has had significant impact on the understanding of stem cell mobilization, angiogenesis, and stem cell niche theory. Dr. Jin was honored as ExecRank Top Chief Medical Officer and Leading Physicians of the World, and has been principle investigator in more than 15 pre-clinical and clinical trials as well as translation researcher in stem cell biology, cancer, and vascular medicine.